- Home
- GAM vs PHVS Comparison
GAM vs PHVS Comparison
Compare GAM & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAM | PHVS |
|---|---|---|
| Founded | 1927 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GAM | PHVS |
|---|---|---|
| Price | $63.98 | $30.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $41.82 |
| AVG Volume (30 Days) | 21.8K | ★ 335.7K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 5.74% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 11.67 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.54 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $52.69 | $15.51 |
| 52 Week High | $66.18 | $31.65 |
Technical Indicators
Market Signals| Indicator | GAM | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 55.05 | 60.31 |
| Support Level | $62.61 | $24.73 |
| Resistance Level | $64.28 | $31.14 |
| Average True Range (ATR) | 1.20 | 1.75 |
| MACD | -0.19 | 0.07 |
| Stochastic Oscillator | 23.88 | 86.19 |
Price Performance
Historical ComparisonAbout GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations. The company invests principally in common stocks believed by management to have growth potential.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.